Field Evaluation of the BD FACSPresto™ Near-Patient CD4 Counter in San Francisco, USA, and Kisumu, Kenya.
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
Presented at AIDS 2014- Melbourne, Australia Field Evaluation of the BD FACSPresto™ Near-Patient CD4 Counter in San Francisco, USA, and Kisumu, Kenya Le D,1 De Pinto S,1 Efros L,1 Lee S,1 Bui N,1 Crow M,1 Mosqueda F,1 Tran A, 1 Waheed S,1 Swaim M,1 Yaneza D,1 Corr N,1 Bhatia S,1 Wu A,1 Mo D,1 Tilahun H,1 Lu B,1 Shea E,2 Ong C,2 Mimba E,3 Akoth B,3 Oyaro B,3 Angira F,3 Wu A,2 Zeh C,3 Chen R,1 Bush-Donovan C,1 Bornheimer S1 1BD Biosciences, San Jose, CA, USA, 2University of California at San Francisco, San Francisco, CA, USA, and 3KEMRI/CDC Research and Public Health Collaboration, Kisumu, Kenya
BD FACSPresto™ Performance Summary Accuracy – San Francisco R2=0.97 Slope= 1.04
BD FACSPresto™ Performance Conclusion In development field studies, the BD FACSPresto Near-Patient CD4 Counter provided accurate and precise clinical results for CD4, %CD4, and total Hb, using capillary or venous samples from HIV patients in hospital clinics in the USA and Kenya. The system is suitable for point-of-care CD4 enumeration.